Institution · Affimed Therapeutics (Germany)

Most cited papers from Affimed Therapeutics (Germany)

Affimed Therapeutics (Germany)

What are the most cited papers from Affimed Therapeutics (Germany)?

The most cited paper from Affimed Therapeutics (Germany) is "Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma" (Christopher James Gibson et al., 2017), with 483 citations. Next come "A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma" (336) and "A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells" (162).

Published TypeFieldAccessCitations

Showing 50 of 62 papers. Every paper with more than 12 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma Christopher James Gibson et al. · Journal of Clinical Oncology Open access	23 Feb 2017	483
2	A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma Achim Rothe, Stephanie Sasse, Max S. Topp et al. · Blood Open access	17 Apr 2015	336
3	A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells Uwe Reusch, Carmen Burkhardt, Ivica Fucek et al. · mAbs Open access	25 Mar 2014	162
4	Of mice and men: hybridoma and recombinant antibodies Melvyn Little, Sergey M. Kipriyanov, Fabrice Le Gall et al. · Immunology Today	Aug 2000	157
5	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies Lucila Nassif Kerbauy et al. · Clinical Cancer Research Open access	13 May 2021	154
6	A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma Nancy L. Bartlett, Alex Francisco Herrera, Eva Domingo‐Doménech et al. · Blood Open access	30 Jul 2020	154
7	CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells Jens H. W. Pahl, Joachim Koch, Jana-Julia Götz et al. · Cancer Immunology Research	7 Mar 2018	138
8	Assuring quality and performance of sustained and controlled release parenterals: Workshop report Diane J. Burgess, Ajaz S Hussain, Thomas S. Ingallinera et al. · AAPS PharmSci Open access	Jun 2002	131
9	A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19 + tumor cells Uwe Reusch, Johannes Duell, Kristina Ellwanger et al. · mAbs Open access	15 Apr 2015	131
10	Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients Katrin S. Reiners, Jörg Keßler, Maike Sauer et al. · Molecular Therapy Open access	5 Mar 2013	111
11	Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies Matthias Eder, Björn Wängler, Stefan H.J. Knackmuss et al. · European Journal of Nuclear Medicine and Molecular Imaging	28 May 2008	102
12	Synergistic Antitumor Effect of Bispecific CD19 × CD3 and CD19 × CD16 Diabodies in a Preclinical Model of Non-Hodgkin’s Lymphoma Sergey M. Kipriyanov, Björn Cochlovius, Holger Schäfer et al. · The Journal of Immunology	Jul 2002	90
13	Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia Uwe Reusch, Kimberly H. Harrington, Chelsea J. Gudgeon et al. · Clinical Cancer Research	17 May 2016	89
14	Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody Fabrice Le Gall, Uwe Reusch, Melvyn Little et al. · Protein Engineering Design and Selection	4 May 2004	84
15	Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers Sheena Pinto, Jens H. W. Pahl, Arndt J. G. Schottelius et al. · Trends in Immunology ReviewOpen access	27 Oct 2022	81
16	Single‐chain antibodies for the conformation‐specific blockade of activated platelet integrin α IIb β 3 designed by subtractive selection from naïve human phage libraries Meike Schwarz, Peter Röttgen, Yoshiazuku Takada et al. · The FASEB Journal	16 Sep 2004	80
17	Generation and Production of Engineered Antibodies Sergey M. Kipriyanov, Fabrice Le Gall · Molecular Biotechnology	2004	75
18	Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial Yago L. Nieto et al. · Nature Medicine Open access	4 Apr 2025	68
19	Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors Susanne Wingert, Uwe Reusch, Stefan H.J. Knackmuss et al. · mAbs Open access	2021	68
20	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy Yucai Wang, Umar Farooq, Brian K. Link et al. · Journal of Clinical Oncology Open access	6 Jun 2019	67
21	Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity Kristina Ellwanger, Uwe Reusch, Ivica Fucek et al. · mAbs Open access	7 Jun 2019	66
22	Inhibition of Melanoma Growth by Targeting of Antigen to Dendritic Cells via an Anti-DEC-205 Single-Chain Fragment Variable Molecule Theron Johnson, Karsten Mahnke, Volker Storn et al. · Clinical Cancer Research	15 Dec 2008	66
23	68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours Matthias Eder, Stefan H.J. Knackmuss, Fabrice Le Gall et al. · European Journal of Nuclear Medicine and Molecular Imaging	15 Feb 2010	66
24	Invasion of Tumorigenic HT1080 Cells Is Impeded by Blocking or Downregulating the 37-kDa/67-kDa Laminin Receptor Chantal Zuber, Stefan H.J. Knackmuss, Georgeta Zemora et al. · Journal of Molecular Biology	13 Feb 2008	63
25	Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy Chantal Zuber, Gerda Mitteregger, Natascha Schuhmann et al. · Journal of General Virology	17 Jul 2008	59
26	Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies Sergey M. Kipriyanov, Gerhard Moldenhauer, Michael Braunagel et al. · Journal of Molecular Biology	Jun 2003	56
27	Assuring Quality and Performance of Sustained and Controlled Release Parenterals: AAPS Workshop Report, Co-Sponsored by FDA and USP Diane J. Burgess, Ajaz S Hussain, Thomas S. Ingallinera et al. · Pharmaceutical Research	Nov 2002	55
28	Anti-LRP/LR-Specific Antibody IgG1-iS18 Significantly Reduces Adhesion and Invasion of Metastatic Lung, Cervix, Colon and Prostate Cancer Cells Aadilah Omar, Uwe Reusch, Stefan H.J. Knackmuss et al. · Journal of Molecular Biology	5 Mar 2012	54
29	Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases Chantal Zuber, Stefan H.J. Knackmuss, Clémence Rey et al. · Molecular Immunology	19 Jun 2007	54
30	Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells Thorsten Gantke, Michael Weichel, Carmen Herbrecht et al. · Protein Engineering Design and Selection Open access	25 Jul 2017	51
31	The 37kDa/67kDa Laminin Receptor acts as a receptor for Aβ42 internalization Bianca Da Costa Dias, Katarina Jovanović, Danielle Gonsalves et al. · Scientific Reports Open access	3 Jul 2014	46
32	A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma Satoko Kakiuchi-Kiyota et al. · Leukemia	10 Jan 2022	44
33	The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells Karen Legler, Charlotte A. E. Hauser, Jan‐Hendrik Egberts et al. · Cell Death and Disease Open access	18 Apr 2018	42
34	Immunosuppressive properties of anti-CD3 single-chain Fv and diabody Fabrice Le Gall · Journal of Immunological Methods	24 Dec 2003	42
35	Effect of tetravalent bispecific CD19×CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells Uwe Reusch, Fabrice Le Gall, Manfred Hensel et al. · International Journal of Cancer	16 Jun 2004	40
36	In Vitro Inhibition of Angiogenesis by Antibodies Directed against the 37kDa/67kDa Laminin Receptor Raksha Khusal, Bianca Da Costa Dias, Kiashanee Moodley et al. · PLoS ONE Open access	12 Mar 2013	40
37	Adhesion and Invasion of Breast and Oesophageal Cancer Cells Are Impeded by Anti-LRP/LR-Specific Antibody IgG1-iS18 Thandokuhle Khumalo, Uwe Reusch, Stefan H.J. Knackmuss et al. · PLoS ONE Open access	18 Jun 2013	38
38	Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies Kristina Ellwanger, Uwe Reusch, Ivica Fucek et al. · Frontiers in Oncology Open access	19 May 2017	36
39	RECRUIT-TandAbs ® : Harnessing the Immune System to Kill Cancer Cells Fionnuala McAleese, Markus Eser · Future Oncology	30 Jun 2012	35
40	Anti-LRP/LR Specific Antibody IgG1-iS18 Impedes Adhesion and Invasion of Liver Cancer Cells Carryn J. Chetty, Thandokuhle Khumalo, Bianca Da Costa Dias et al. · PLoS ONE Open access	5 May 2014	31
41	LRP/LR Antibody Mediated Rescuing of Amyloid-β-Induced Cytotoxicity is Dependent on PrPc in Alzheimer’s Disease Emma C. Pinnock, Katarina Jovanović, Maxine G. Pinto et al. · Journal of Alzheimer s Disease	14 Dec 2015	30
42	Knock-Down of the 37kDa/67kDa Laminin Receptor LRP/LR Impedes Telomerase Activity Kerrilyn Naidoo, Sibusiso Tebogo Malindisa, Tyrone C. Otgaar et al. · PLoS ONE Open access	6 Nov 2015	30
43	Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Sergey M. Kipriyanov, Fabrice Le Gall · PubMed	Mar 2004	30
44	Anti-LRP/LR specific antibodies and shRNAs impede amyloid beta shedding in Alzheimer's disease Katarina Jovanović, Danielle Gonsalves, Bianca Da Costa Dias et al. · Scientific Reports Open access	19 Sep 2013	29
45	Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR by shRNAs rescue cells from Aβ42 induced cytotoxicity Bianca Da Costa Dias, Katarina Jovanović, Danielle Gonsalves et al. · Scientific Reports Open access	19 Sep 2013	28
46	Design and conduct considerations for studies in patients with hepatic impairment Paulien G. M. Ravenstijn, Manoranjenni Chetty, Pooja Manchandani et al. · Clinical and Translational Science Open access	30 Sep 2022	27
47	Alternative Antibody Formats Fabrice Le Gall, Melvyn Little · Cambridge University Press eBooks Book chapter	27 Jul 2009	27
48	T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16 Lisa M. Pörtner, Kathrin Schönberg, Maryam Hejazi et al. · Cancer Immunology Immunotherapy Open access	13 Sep 2012	26
49	Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11 Johannes Duell, D. Slavkovic Lukic, Margarete M. Karg et al. · Journal of Immunotherapy	14 May 2019	24
50	Generation of Bispecific and Tandem Diabodies Sergey M. Kipriyanov · Methods in molecular biology Book chapter	2009	24

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.